NL-OMON22158
招募中
不适用
Improvement of Prostate Cancer Diagnosis: a Multi-center, Observational Evaluation of Pre-biopsy MRI-pathways
/a0 个研究点目标入组 700 人待定
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Prostate cancer
- 发起方
- /a
- 入组人数
- 700
- 状态
- 招募中
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Biopsy\-naïve men, aged 18\-80 years.
- •\- Clinical suspicion of prostate cancer (i.e. PSA \= 3\.0 ng/ml and/or abnormal DRE).
- •\- Men must be able to comprehend and sign an informed consent and must be able to comprehend and sign an MRI screening form (to search for metal device/foreign bodies/claustrophobia).
排除标准
- •\- History of previous prostate biopsy.
- •\- Already proven prostate cancer or history of PCa.
- •\- Contraindications for an MRI scan (with gadolinium contrast).
- •\- History of invasive treatments for BPH or lower urinary tract symptoms (LUTS), e.g. transurethral
- •resection of the prostate; heat, laser or ultrasound treatments in the last 12 months.
结局指标
主要结局
未指定
相似试验
尚未招募
不适用
Prostate cancer diagnosis by multiparametric ultrasoundProstate cancerprostatic adenocarcinoma10038597NL-OMON54171Academisch Medisch Centrum25
已完成
不适用
Biparametric MRI for Detection of Significant Prostate CancerProstate CancerNCT02584179Herlev Hospital1,063
Unknown
不适用
Early and Accurate Detection of Prostate Cancer in General PracticeProstate CancerProstate NeoplasmProstate AdenocarcinomaNCT03431753Aarhus University Hospital3,000
招募中
不适用
Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer PatientProstate CancerProstate NeoplasmNCT05422105Primo Biotechnology Co., Ltd230
撤回
不适用
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMCProstate CancerProstate AdenocarcinomaProstate Cancer MetastaticNCT03494803HKGepitherapeutics